Management of Respiratory Failure in Patients with COVID-19 and Multiple Myeloma

Slamet Hadi Santoso, Arie Zainul Fatoni


Background: Cancer patients have higher risk of getting COVID-19. Individuals with malignancy who infected COVID-19 often underwent prolonged hospitalization or death. Here, we report respiratory failure management of of COVID-19 patient with multiple myeloma (MM).

Case: A 66-year-old man came with complaints of shortness of breath. The patient was intubated and treated in the intensive care COVID. Patients with a history of multiple myeloma and who have chemotherapy cycle. The laboratory results showed an increase in markers of inflammation, hypoalbuminemia, and bicytopenia. The results of the polymerase chain reaction swab were positive.  There are 4 managements in this patient, airway management: intubation and ventilator settings using the Lung Protective Strategy principle. Management Breathing: administration of antibiotics according to sputum culture results. Circulation Management: Fluid management using a non-invasive Contractility Index (ICON) monitor. Management of Disability: Spontaneous Awakening Trial (SAT) and Spontaneous Breathing Trial (SBT) when the aggravating disease has been handled.

Conclusion: Management of respiratory failure in patients with multiple myeloma and COVID-19 infection is primarily focused on supportive care such as airway management, breathing management, fluid management and disability management.


COVID-19; multiple myeloma; respiratory failure

Full Text:



Bi J, Lin Y, Zhong R, et al. Prevalence and clinical characterization of cancer patients with asymptomatic SARS-CoV-2 infection history. J Infect. 2020;81(6):e22-e24. doi:10.1016/j.jinf.2020.07.018

Jindal V, Sahu KK, Gaikazian S, Siddiqui AD, Jaiyesimi I. Cancer treatment during COVID-19 pandemic. Med Oncol. 2020;37(7):58.doi:10.1007/s12032-020-01382-w

Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708 1720. doi:10.1056/NEJMoa2002032

Terpos E, Engelhardt M, Cook G, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;34(8):2000-2011. doi:10.1038/s41375-020-0876-z

Cunningham, AC, Goh HP, David K. Treatment of COVID-19: old tricks for new challenges. Critical Care, 2020; 24(91): 1-2.

Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. Journal of Community Empowerment for Health, 2020, 3.2: 77.

Fatoni, AZ, R Rakhmatullah. Acute respiratory distress syndrome (ARDS) pada pneumonia COVID-19. Journal of Anaesthesia and Pain. 2021;2(1):11-24.

Alshukry A, Ali H, Ali Y, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients in Kuwait. PLoS One. 2020;15(11):e0242768. doi:10.1371/journal.pone.0242768

Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25. doi:10.1016/j.jinf.2020.04.021

Chavez-MacGregor M, Lei X, Zhao H, et al. Evaluation of COVID-19 mortality and adverse outcomes in us patients with or without cancer. JAMA Oncol. 2022;8(1):69–78. doi:10.1001/jamaoncol.2021.5148

Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 2020;508:254-266. doi:10.1016/j.cca.2020.05.044



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.